"Fostering Massachusetts' life science ecosystem", Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center (MLSC). Presented at Better innovation in biotech, part of MIT Startup Exchange cluster workshop series on 2/26/15, see http://startupexchange.mit.edu/startupexchange/html/index.html#viewOpportunity/51
Showcasing the new initiative, MIT Startup Exchange, introducing the workshop What's next in mobile at MIT in January 2015. By Trond Undheim, PhD, Lead, MIT Startup Exchange.
Showcasing the new initiative, MIT Startup Exchange, introducing the workshop What's next in mobile at MIT in January 2015. By Trond Undheim, PhD, Lead, MIT Startup Exchange.
Better Biotech Innovation by Improving the Ecosystem by Tim Charlebois, VP In...MIT Startup Exchange
Keynote: "Better Biotech Innovation by improving the ecosystem," Tim Charlebois, Ph.D., VP of technology and innovation strategy, Pfizer Biotherapeutics. Presented as a keynote speech at Better innovation in Biotech, part of MIT Startup Exchange cluster workshop series, see http://startupexchange.mit.edu/startupexchange/html/index.html#viewOpportunity/51
Welcome: "MIT's Cybersecurity startups," Trond Undheim, Ph.D., Lead, MIT Startup Exchange, MIT ILP (host), CYBERSECURITY INNOVATION (5/28), MIT STEX cluster workshop, Thursday May 28, 2015, 8:30 AM to 11:30 AM, ,One Main Street, Cambridge, MA.
Through the creation of sector-specific Manufacturing USA Centers, the Massachusetts Manufacturing Innovation Initiative (M2I2) will advance innovations and job growth within the state through cross-collaboration among companies, universities, national labs, government, incubators, accelerators and other academic and training institutions.
020719 day one accelerator webinar presentationDayOne
Details of the application process for the DayOne accelerator. Applications close July 26th. Details at https://www.dayone.swiss/dayone/accelerator.html
The DayOne accelerator supports healthcare innovators with 50,000CHF in cash and access to Europe's leading healthcare ecosystem. The focus of the program are ventures that can have an impact on the health and wellbeing of children and young people
Presentation on success factors for technology based startups given by a doctoral student at MIT Sloan for graduate students in departments touching on nanotech.
Calit2 – Increasing Interaction Between Industry and University ResearchersLarry Smarr
08.03.31
Presentation
Panel on Best Practices in University-Industry Research Collaborations 2008 Engineering Deans Institute (EDI)
“Strategic University-Industry Partnerships for Innovation”
American Society for Engineering Education
University of California, San Diego
Title: Calit2 – Increasing Interaction Between Industry and University Researchers
La Jolla, CA
Europe 2014-2020: programme de recherche & innovation Horizon 2020UNITEC
Commission Européenne, présentations de la Délégation générale Société de l'Information à la délégation d'Aquitains conduite par AEC, 30 janvier 2012:
le programme horizon 2020, programme cadre européen pour la recherche et l’innovation, regroupe et remplacera à partir de 2014 2014 les actuels Programme Cadre de recherche (7e PCRD), Programme Cadre pour la Compétitivité et l'Innovation (CIP) et Institut Européen de Technologie (IET)
"Lessons from spinning out biotech firms from university labs", Professor Jeff M Karp, Associate Professor Harvard Medical School, Co-Director of the Center for Regenerative Therapeutics at the Brigham and Women's Hospital, MIT affiliate faculty, Harvard-MIT Division of Health Sciences and Technology. Karp has co-founded the startups Gecko Biomedical and Skintifique.
Reinventing Life Sciences: How emerging ecosystems fuel innovationIBM in Healthcare
Persistent disruptive forces in life sciences now threaten traditional business models over the medium to long term. While high rates of return and strong performance may have masked these forces in the past, today they must be recognized and addressed. Organizations need new ways to continue to thrive despite such hurdles.
This latest research study by IBM Instritute of Business Value in collaboration with the University of California, San Diego and Oxford Economics, led to a target innovation model that can guide organizations to discover operational efficiencies, nurture new growth and get positioned more strategically in the new life sciences and healthcare ecosystem.
Better Biotech Innovation by Improving the Ecosystem by Tim Charlebois, VP In...MIT Startup Exchange
Keynote: "Better Biotech Innovation by improving the ecosystem," Tim Charlebois, Ph.D., VP of technology and innovation strategy, Pfizer Biotherapeutics. Presented as a keynote speech at Better innovation in Biotech, part of MIT Startup Exchange cluster workshop series, see http://startupexchange.mit.edu/startupexchange/html/index.html#viewOpportunity/51
Welcome: "MIT's Cybersecurity startups," Trond Undheim, Ph.D., Lead, MIT Startup Exchange, MIT ILP (host), CYBERSECURITY INNOVATION (5/28), MIT STEX cluster workshop, Thursday May 28, 2015, 8:30 AM to 11:30 AM, ,One Main Street, Cambridge, MA.
Through the creation of sector-specific Manufacturing USA Centers, the Massachusetts Manufacturing Innovation Initiative (M2I2) will advance innovations and job growth within the state through cross-collaboration among companies, universities, national labs, government, incubators, accelerators and other academic and training institutions.
020719 day one accelerator webinar presentationDayOne
Details of the application process for the DayOne accelerator. Applications close July 26th. Details at https://www.dayone.swiss/dayone/accelerator.html
The DayOne accelerator supports healthcare innovators with 50,000CHF in cash and access to Europe's leading healthcare ecosystem. The focus of the program are ventures that can have an impact on the health and wellbeing of children and young people
Presentation on success factors for technology based startups given by a doctoral student at MIT Sloan for graduate students in departments touching on nanotech.
Calit2 – Increasing Interaction Between Industry and University ResearchersLarry Smarr
08.03.31
Presentation
Panel on Best Practices in University-Industry Research Collaborations 2008 Engineering Deans Institute (EDI)
“Strategic University-Industry Partnerships for Innovation”
American Society for Engineering Education
University of California, San Diego
Title: Calit2 – Increasing Interaction Between Industry and University Researchers
La Jolla, CA
Europe 2014-2020: programme de recherche & innovation Horizon 2020UNITEC
Commission Européenne, présentations de la Délégation générale Société de l'Information à la délégation d'Aquitains conduite par AEC, 30 janvier 2012:
le programme horizon 2020, programme cadre européen pour la recherche et l’innovation, regroupe et remplacera à partir de 2014 2014 les actuels Programme Cadre de recherche (7e PCRD), Programme Cadre pour la Compétitivité et l'Innovation (CIP) et Institut Européen de Technologie (IET)
"Lessons from spinning out biotech firms from university labs", Professor Jeff M Karp, Associate Professor Harvard Medical School, Co-Director of the Center for Regenerative Therapeutics at the Brigham and Women's Hospital, MIT affiliate faculty, Harvard-MIT Division of Health Sciences and Technology. Karp has co-founded the startups Gecko Biomedical and Skintifique.
Reinventing Life Sciences: How emerging ecosystems fuel innovationIBM in Healthcare
Persistent disruptive forces in life sciences now threaten traditional business models over the medium to long term. While high rates of return and strong performance may have masked these forces in the past, today they must be recognized and addressed. Organizations need new ways to continue to thrive despite such hurdles.
This latest research study by IBM Instritute of Business Value in collaboration with the University of California, San Diego and Oxford Economics, led to a target innovation model that can guide organizations to discover operational efficiencies, nurture new growth and get positioned more strategically in the new life sciences and healthcare ecosystem.
The next frontier in mobile computing: Your skin, biology, and the brain in t...MIT Startup Exchange
The next frontier in mobile computing: Your skin, biology, and the brain in the body, presentation at MIT Startup Exchange ICT cluster workshop on What's next in Mobile, by Rob Goldberg, PhD, CEO & co-founder, Neumitra.
In search of the next big thing in Mobile, a Samsung perspectiveMIT Startup Exchange
In search of the next big thing in Mobile, a Samsung perspective, presentation at MIT Startup Exchange ICT cluster workshop at MIT in January 2014, by Raymond Liao, Managing Director, Strategic Investment, Open Innovation Center, Samsung.
The greatest platform for innovation ever: trends in VC and MIT mobile innova...MIT Startup Exchange
VC Scott Johnson from NAVfund outlines what he sees as the world's greatest investment opportunity--the mobile platform-to an audience of entrepreneurs, faculty, students, and industry at MIT in January 2015. See http://startupexchange.mit.edu/startupexchange/html/index.html#viewOpportunity/48
Smarter Drivers. Safer Roads, by Chief Scientist and Founder, Sam Madden, Cambridge Mobile Telematics. Presentation held at What's next in mobile, a MIT Startup Exchange ICT cluster workshop on 1/29/15.
WE Europe 2015: Innovating in disruptive ecosystems: lessons from the life sc...Society of Women Engineers
Leading organizations have a clear focus on innovation. They recognize that effective and sustained innovation drives both value creation and competitiveness.This presentation will highlight how the most successful organizations approach innovation and pursue distinct strategies in innovation organization, culture and process that can help all organizations innovate like an "outperformer". To illustrate our findings we present survey data (from 1000 C-Suite executives and 750 Life Sciences executives) and case studies from an industry that is currently going through significant disruption - the life sciences industry.
"The Future of Food," Manoj Fenelon, Director of Foresight, PepsiCo. MIT Startup Exchange
"The Future of Food," Manoj Fenelon, Director of Foresight, PepsiCo. Presented at MIT Startup Exchange (STEX) cluster workshop on Food Tech Innovation, 22 April, 2015.
Future opportunities for food tech product innovation from a research perspec...MIT Startup Exchange
"Future opportunities for food tech product innovation from a research perspective," Omer Yilmaz, Ph.D., Assistant Professor of Biology, MIT and gastrointestinal pathologist, Massachusetts General Hospital and Harvard Medical School. Presented at MIT Startup Exchange (STEX) cluster workshop on Food Tech Innovation, 22 April 2015, MIT. Twitter" #STEXfood
Food, Sensors, Startups - The Road Ahead From a MIT perspectiveMIT Startup Exchange
"Food, sensors, startups - the road ahead from an MIT perspective," Timothy M. Swager, John D. MacArthur Professor of Chemistry at MIT and Faculty Director of the Deshpande Center for Technological Innovation. Presented at the MIT Startup Exchange (STEX) cluster workshop on Food Tech Innovation, 22 April 2015, MIT. Twitter: #STEXfood.
Similar to "Fostering Massachusetts' life science ecosystem", Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center (MLSC).
Presentation of Susan Bannister (Massachusetts Life Sciences Center, Former President and CEO) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
mHealth Israel_Mony Weschler_Montefiore_How Data Exchange Is Essential In Sup...Levi Shapiro
Presentation for mHealth Israel by Mony Weschler, Senior Director Applications Strategy and Innovation, Albert Einstein College of Medicine, Montefiore Medical Center. Theme: How Data Exchange Is Essential In Support of New Technologies & Healthcare Innovation. This presentation has three objectives:
1) Discuss IT governance components that positioned Montefiore to achieve extensive community outreach efforts
2) Review strategies for incorporating innovation and new technologies into existing processes.
3) Identify the data exchange challenges
Year after year, technology has played a role in changing the way that health care is delivered. Now in 2014, as technology continues to advance, consumers are demanding more convenient and cost effective care through increased use of mHealth and Telehealth. The mHealth + Telehealth World 2014 is must attend event for health care executives interested in learning how to most efficiently utilize Telehealth programs and mHealth practices to improve patient outcomes by promoting interoperability, sustainability, provider interest, and consumer engagement. Hear case studies, understand the ROI, and discuss ways to address critical issues – including licensing and security issues – of digital health practices.
http://www.worldcongress.com/events/HL14028/
The external healthcare environment is changing rapidly and providers are under increasing pressure to innovate with increasing speed and efficiency.
Be it experimenting with new care delivery models to improve care coordination, redesigning workflows to enhance efficiency, or developing new products that improve clinical outcomes, hospitals and their service lines are looking for effective ways to harness the creative power of physicians and employees to solve problems that matter. However, few organizations innovate in an orderly, reliable way.
Great ideas remain captive in the heads of physicians and employees and one-off attempts to spur innovation through “hack-a-thons” and “pitch days” prove disappointing. As an academic medical center and a world leader in orthopedics, Hospital for Special Surgery has a long history of results-oriented innovation.
In this webinar, we will share:
– HSS’ systematic approach for driving innovation
– strategies for generating new insights and developing novel solutions
– processes for piloting and testing new ideas
– guiding principles for creating a culture of innovation
– advice on how to build your very own innovation infrastructure
About the Speaker:
Mark Angelo is Vice President, Innovation & Business Development for Hospital for Special Surgery. Mark joined HSS in 2009 and has held various senior management positions at the Hospital across operations, strategy and business development. As Vice President, Innovation & Business Development, Mark is responsible for advancing hospital strategic priorities related to quality and efficiency, innovation, growth and diversification. One of his key responsibilities includes leading the Operational Excellence program, a hospital-wide initiative that leverages industrial engineering principles to maximize quality and efficiency. Mark also leads the HSS Innovation Center whose mission is to support the development and commercialization of early-stage technologies and solutions.
Prior to joining HSS, Mark worked as a management consultant for Monitor Group where he specialized in operations strategy and organizational design. Mark holds a Bachelor of Applied Science in Biomedical Engineering from the University of Toronto and a Master of Business Administration from Harvard Business School.
EuroBioForum 2013 - Day 2 | Mark PoznanskyEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
Presentation of Zayna Khayat (MaRS Discovery District, Health System Innovation; MaRS EXCITE) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Take your Idea. Develop your Product. Test it, Sell it, and Exit. Innovative clinical minds face difficulties actualizing great product ideas because of the complexities associated with healthcare product development. A successful healthcare innovation development process involves integrating many complex disciplines at the highest level of quality in order to provide patients with the safest and most effective treatment options. As a result, many innovators never begin to develop their ideas because of intimidation or lack of resources. Some innovators go through the stressful and costly undertaking of an improvised development process that ultimately leads to a less than optimum product and poor financial returns. In order to solve this problem, we created a comprehensive platform to efficiently translate ideas into effective and successful healthcare products.
Similar to "Fostering Massachusetts' life science ecosystem", Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center (MLSC). (20)
Energy storage innovation, both at micro and grid scale, is at the cusp of several major breakthroughs which are already impacting consumer electronics and autonomous transportation and several other consumer and industrial uses. Battery prices have come down significantly. Product options are available. With that comes commercial opportunities, policy challenges, industry disruption, new business models, and an array of new startups. What are some emerging energy storage technologies? Who are the players? What adjacent technologies are moving pieces in this game (IoT, cloud, EVs, utilities, distributed generation, transportation networks, mobility tech, sensors etc.). What will this world look like for industry, startups, governments, and consumers? How can existing infrastructure evolve to enable making the most of such breakthroughs? What are the regulatory obstacles in the five key markets where energy storage might emerge first (EU, Australia, Latin-America, South Africa, and USA)?
Building Trust in a Tense Information Society, Daniel Weitzner, Director, MIT...MIT Startup Exchange
Building Trust in a Tense Information Society, Daniel Weitzner, Director, MIT CSAIL Decentralized Information Group. Keynote held at MIT Startup Exchange (STEX) Cybersecurity Innovation workshop (5/28) at MIT on Thursday May 28, 2015, 8:30 AM to 11:30 AM, at One Main Street, Cambridge, MA, USA.
Cybersecurity investment trends, Chris Lynch, Partner, Atlas Ventures. MIT Startup Exchange
"Cybersecurity investment trends" Chris Lynch, Partner, Atlas Ventures. Cybersecurity Innovation (5/28), MIT Startup Exchange (STEX), Thursday May 28, 2015, 8:30 AM to 11:30 AM, at One Main Street, Cambridge, MA.
"MIT's Food Tech Startups," Trond Undheim, Ph.D., Lead, MIT Startup Exchange, MIT ILP (host). Presented at MIT Startup Exchange (STEX), cluster workshop on Food Tech Innovation, 22 April, 2015, MIT.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
This session provides a comprehensive overview of the latest updates to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (commonly known as the Uniform Guidance) outlined in the 2 CFR 200.
With a focus on the 2024 revisions issued by the Office of Management and Budget (OMB), participants will gain insight into the key changes affecting federal grant recipients. The session will delve into critical regulatory updates, providing attendees with the knowledge and tools necessary to navigate and comply with the evolving landscape of federal grant management.
Learning Objectives:
- Understand the rationale behind the 2024 updates to the Uniform Guidance outlined in 2 CFR 200, and their implications for federal grant recipients.
- Identify the key changes and revisions introduced by the Office of Management and Budget (OMB) in the 2024 edition of 2 CFR 200.
- Gain proficiency in applying the updated regulations to ensure compliance with federal grant requirements and avoid potential audit findings.
- Develop strategies for effectively implementing the new guidelines within the grant management processes of their respective organizations, fostering efficiency and accountability in federal grant administration.
A process server is a authorized person for delivering legal documents, such as summons, complaints, subpoenas, and other court papers, to peoples involved in legal proceedings.
"Fostering Massachusetts' life science ecosystem", Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center (MLSC).
1. Investing in the State of Innovation
Presented to the MIT Startup Exchange Workshop
February 26, 2015
Developing and Maintaining the World’s
Leading Life Sciences Ecosystem:
The Massachusetts Life Sciences Center
Strategy and Programming Overview
3. 3
What is the Massachusetts Life Sciences
Initiative?
A 10-year, $1 billion initiative to invest in the state’s life sciences
sectors, enacted by the Massachusetts legislature in June 2008.
The Initiative is administered by the Massachusetts Life Sciences
Center (MLSC), which serves as the “hub” of the state’s life
sciences community.
Encourage life sciences innovation through investments in good science and good
business
Strengthen and protect Massachusetts’ global leadership position in the life sciences
Accelerate the commercialization of promising treatments, therapies and cures
Create jobs and drive economic development
Goals of the Life Sciences Initiative:
4. 4
What Life Sciences Sectors are Targeted
by the MLSC?
Biotechnology Diagnostics PharmaceuticalsMedical Devices Bioinformatics
Primary Sectors
Science, Technology, Engineering, Math (STEM)
AND…..
• Administration
• Animal Husbandry/Care
• Advertising and
Communications
Skills
• Sales and
Marketing
• Finance
• IT
• Legal and
Regulatory
• Logistics
Management
• Project
Management
5. 5
Annual appropriation
Included in the Massachusetts Legislature’s state budget
The MLSC has the most “discretion” over the use of these funds
Annual authorization
Authorized by the MA
Executive Office of
Administration and Finance
Used to award tax incentives
and credits
Annual share of Massachusetts’
bond capacity
Determined by the MA Executive
Office of Administration and Finance
Used for capital and
infrastructure projects
The MLSC is Funded from Three Sources
• 10 Years
• $1 Billion
Investment
6. 6
The MLSC is a Public-Private Partnership,
Governed by a Multi-Disciplinary Board of Directors*
• Secretary of Housing and Economic Development
Jay Ash
• Secretary of Administration and Finance
Kristen Lepore
• President of the University of Massachusetts System
Robert Caret, Ph.D.
• A researcher involved in the commercialization of biotechnology,
pharmaceuticals or medical diagnostic products
Lydia Villa-Komaroff, Ph.D., Director and CSO, Cytonome/ST
• A physician licensed to practice medicine in the Commonwealth and
affiliated with an academic medical center
Edward Benz, M.D., President & CEO, Dana-Farber Cancer Institute
• A person with financial expertise in the life sciences
Peter Parker, President, BioInnovation LLC, Co-Founder, LabCentral
• A CEO of a Massachusetts based life sciences corporation
Adelene Perkins, Chair, President and Chief Executive Officer of Infinity
Pharmaceuticals, Inc.
*Board membership as of January 2015
7. 7
A “Blue Ribbon” Multi-disciplinary Scientific
Advisory Board* Guides Investment Decisions
CHAIR: Harvey F. Lodish, Ph.D.,
Whitehead Institute and Massachusetts Institute of Technology (MIT)
Academia
James J. Collins,
Ph.D., Massachusetts
Institute of Technology
John M. Collins, Ph.D.,
Center for Integration of
Medicine & Innovative
Technology (CIMIT)
Robert D’Amato, M.D.,
Ph.D., Center for
Macular Degeneration
Research , Harvard
Medical School and
Boston Children’s
Hospital
Glenn R. Gaudette,
Ph.D.,
Worcester Polytechnic
Institute (WPI)
Judith Lieberman,
Ph.D.,
Immune Disease
Institute, Boston
Children’s Hospital and
Harvard Medical School
Lita L. Nelsen,
Massachusetts Institute
of Techonolgy
Barbara Osborne,
Ph.D.,
UMass Amherst
Guillermo Tearney,
M.D., Ph.D.,
Harvard Medical School,
Harvard-MIT Division of
Health Sciences and
Technology (HST) and
Massachusetts General
Hospital
David Walt, Ph.D.,
Tufts University School
of Medicine
Philip Zamore, Ph.D.,
UMass Medical School
Frederick J. Schoen,
M.D., Ph.D. Professor
Harvard Medical School
Industry
James Barry, Ph.D.,
Inspire MD, Inc.
Dalia Cohen, Ph.D.,
ALN Associates
José-Carlos Gutiérrez-
Ramos, Ph.D.,
Pfizer
Dale Larson,
Draper Laboratory
Alan Smith, Ph.D.,
CBE, FRS, Genzyme
(Retired)
Alison Lawton
Board of Directors for
Cubist Pharmaceuticals
and Verastem Inc.
Venture Capital
Kevin Bitterman,
Ph.D.,
Polaris Venture Partners
T. (Teo) Dagi, M.D.,
M.B.A.,
Queens University
Belfast & Broadview
Ventures
Andrew Jay, DMD,
Siemens Venture
Capital
Henry Kay
Boston Harbor Angels
Carmichael Roberts,
Ph.D., M.B.A.,
North Bridge Venture
Partners
Lauren Silverman,
Ph.D.,
Novartis Option Fund
Frederick Jones, M.D.
Broadview Ventures
Entrepreneurs
Alison Taunton-Rigby,
Ph.D. ,
RiboNovix, Inc.
Hillel Bachrach
Viztech & UltraSPECT
*SAB membership as of January 2015
8. 8
The MLSC’s Strategy is to Invest in Innovation
Capacity
What is Innovation Capacity?
“The ability to produce and commercialize a flow of innovative technology over
the long term.”
Furman, Porter and Stern, 2002
“Geographies with high innovative capacity usually develop faster economically,
attract highly skilled populations, and experience rising incomes and trade.”
(Harvard Business School 2001)
Why Invest in Innovation Capacity?
• Optimal role for the public sector
• All stakeholders and regions benefit from the investment
Create GrowDevelop Sustain
9. 9
How is the MLSC Implementing the Strategy?
A Portfolio of Investments That Target Key Enablers of Life Sciences
Innovation Capacity
Collaboration
• Biomanufacturing Roundtable
• International Collaborative
Industry Program (ICIP)
• International Partnership
Assistance Portal
• Neuroscience Consortium
• Universal Partnership Program
(UP)
Translational Research
• Co-operative Research Grants
Infrastructure
• Equipment and Supply Grants to
Middle, Voc Tech and Public
High Schools
• New Spaces for Research,
Training, Business Incubating,
Biomanufacturing and
Computing
Workforce Development
and Job Growth
• Grants to Community-Based
STEM Programs
• Internship Challenge Program
• Tax Incentives
Entrepreneurship
• Grants for Business Plan
Competitions
• Milestone Achievement Program
(MAP)
• Accelerator Loan Program
• Small Business Matching Grant
Program (SBMG)
Think
BIG
10. 10
Investments Also Coalesce the Massachusetts
Life Sciences “Cluster” into an “Ecosystem”
Massachusetts has a high
concentration of
universities, research
hospitals, skilled workers,
entrepreneurs, mature
companies and investors
In a high-performing
innovation ecosystem
these components work
well individually and
together!
11. 11
MLSC Investments are Revving Up the
Massachusetts Life Sciences Ecosystem
Collaboration
K-12 STEM
Programs
Translational
Research
Advanced and Bio-
Manufacturing
Leverage:
Internships Tax Incentives
Early Stage Companies and
Entrepreneurship
Voc Tech and High
School Equipment
Capital Projects in
Academic Institutions
12. 12
MLSC Investments are Well-Distributed
Across the Commonwealth
Lab Central Incubator
Cambridge
$10 Million
Translational Center for the Cure of
Diabetes
Joslin Diabetes Center
Boston
$5 Million
Center for Personalized Cancer Treatment
UMass Boston
Boston
$10 Million $55 Million In
Greater Boston
Massachusetts Accelerator
for Biomanufacturing
Fall River
$25.6 Million
Center for Regenerative Biology
Marine Biological Laboratory
Woods Hole
$10 Million
$43 Million in
Southeast and South Coast
Life Sciences Consortium of the
North Shore
Beverly
$5 Million
Mass Medical Device Development
Center (M2D2) Expansion
UMass Lowell
Lowell
$4 Million
$23 Million in
North Shore
New Science Center
Framingham State University
Framingham
$3 Million
Wastewater Treatment Facility
Town of Framingham
$12.9 Million
$16 Million in
Metrowest
Albert Sherman Center
UMass Medical School
Worcester
$90 Million
Gateway Park
Biomanufacturing Education
and Training Center
Worcester
$5.15 Million $111 Million in
Central MA
Commonwealth Computational
Cloud for Data Driven Biology
Mass Green High Performance
Computing Center (MGHPCC)
Holyoke
$4.5 Million
Three New Translational Science Centers
UMass Amherst
Amherst
$95 Million
Healthcare Informatics &
Technology Innovation Center
Baystate Med. Ctr.
Springfield
$5.5 Million
$119 Million in
Western MA
*
*
Strengthened core competencies that are unique to each region build
innovation capacity statewide
15. 15
MLSC Investments Have Funded the Creation
of New Research Space
Since 2007, over five million square feet of commercial lab space
have been added to the state’s inventory
Source: Colliers Meredith & Grew, Life Science Review, 2007-2013
Courtesy of MassBio Industry Trade Association 2014
16,064,000
17,021,000
18,437,000
2007 2009 2011 2013
18,687,000
2014
21,204,000
MLSC investments have helped fund 1.5M sq. ft. of this
new research space since 2008
16. 16
MLSC Investments Have Funded Business
Incubating and Biomanufacturing Spaces
$5M MLSC grant to WPI for a
Biomanufacturing Education
and Training Center (BETC) in
Worcester; industry matches to
date are $50M
$13.7M MLSC grant to the
Town of Framingham for
wastewater management
enabled Genzyme to build a
$410M Fabry manufacturing
facility
$10M MLSC grant to build
Lab Central in Kendall
Square; industry and VC
matching investment to date
is $30M
17. 17
Biogen Idec
Cambridge
MLSC Tax Incentives Have Contributed to
Significant Company Growth in MA
Shire
Lexington
PerkinElmer
Waltham
Cubist
Lexington
18. 18
The MLSC Has Accelerated the Pace of New
Company Arrivals and Expansions in MA
19. 19
MLSC Investments Helped Lead Massachusetts
Out of the Economic Recession
0
5
10
15
20
MLSC Targeted Sectors Massachusetts
Employment Growth in MLSC Targeted
Sectors (2006-2012)
20. 20
MA Now Ranks #1 in Total Life Sciences
Employment On a Per Capita Basis
17,363
Massachusetts
9,477
Pennsylvania 1.8X higher than in Pennsylvania
9,524
California 1.8X higher than in California
5,744
Florida 3.0X higher than in Florida
13,592
New Jersey 1.3X higher than in New Jersey
7,392
New York 2.3X higher than in New York
Total Life Sciences Employment, per One Million Population by U.S.
State 2010-2012
21. 21
The Life Sciences Sectors are Now a Major Part
of the Massachusetts Economy
Total Massachusetts Life Sciences Employment:
113,678
Life Sciences Employment By Sector: 2010-2012
22. 22
533.8
447.0
345.6
325.4
265.9
222.5
206.2
164.5
124.8 122.0 115.7 113.7 111.4
86.4 84.2
46.8
0.0
100.0
200.0
300.0
400.0
500.0
600.0
* Excluding Life Sciences
Employment in the Life Sciences is Now as
High as the State’s Entire Construction Industry
Employment by Major Employment Sector (in 000's)
Massachusetts 2010-2012
23. 23
The Life Sciences Initiative Has Made MA an
International Target for Investment and Growth
Sources: MassBio, membership reports, survey, Boston Business Journal Book of Lists, 2013
Over half of
our 21 leading
biopharma
companies
employ 1,000
or more
workers
Nearly one-
third of our
leading
companies had
little or no
presence in MA
before 2004!
Rank # Company Jobs
1 Genzyme (Sanofi) 4,600
2 Pfizer 2,600
3 Biogen Idec 2,300
4 Novartis 2,100
5 PAREXEL International 2,000
6 Covidien 1,800
7 Hologic 1,775
8 EMD Millipore 1,756
9 Shire 1,500
10 Thermo Fisher Scientific 1,450
Vertex 1,450
12 Millenium Takeda Oncology 1,204
13 AstraZeneca 948
14 Charles River Laboratories 930
15 Abbot Laboratories 850
16 EMD Serono 704
17 Nova Biomedical 700
18 Cubist 638
19 Sunovion Pharmaceuticals (DS) 593
20 Merck 500
21 Bristol-Myers Squibb 400
24. 24
Global Leaders are Moving Their U.S.
Headquarters to MA
GE Healthcare Life
Sciences Moves to
Marlborough HQ (8/20/14)
Healthcare Giant
Baxter International
Is Moving to
Cambridge (8/27/14)
Shire to Move US HQ and 500 Jobs to
Greater Boston (11/19/14)
Shire to Buy NPS Pharmaceuticals for
$5.2 Billion and Considering Moving
Many of NPS’s 400 Employees to its
Lexington Campus (1/1/15)
Pfizer completes move of
research unit to
Massachusetts (9/8/11)
Merck KGaA moving
US base to Billerica,
Millipore deal also
expected to bring new
jobs to state (3/4/10)
Amgen enters
heavyweight fray for
Kendall Square's few
remaining blocks of
space (8/19/14)